Regenacy Promotes Simon Jones to CEO, Walter Ogier Stays on Board

Regenacy Pharmaceuticals has promoted Simon Jones to president and CEO of the clinical-stage drug developer. Jones had served as chief operating officer and senior vice president of preclinical development since the Boston company spun out of Acetylon Pharmaceuticals last year in a deal that gives Celgene (NASDAQ: [[ticker:CELG]]) partial rights to two drugs.

Before Regenacy, Jones was senior vice president of biology and preclinical development at Acetylon. Jones succeeds Walter Ogier, who will remain on Regenacy’s board of directors.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.